DUBLIN–(BUSINESS WIRE)–Feb 9, 2021–
The "Matrix Metalloproteinase 9 – Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com’s offering.
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resorption. MMP9 along with elastase, appears to be a regulatory factor in neutrophil migration across the basement membrane. MMP9 may play an important role in wound repair, angiogenesis and neovascularization.
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively.
The report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Gastrointestinal, Cardiovascular, Musculoskeletal Disorders, Ophthalmology, Immunology, Infectious Disease, Respiratory and Undisclosed which include indications Neuropathic Pain (Neuralgia), Osteoarthritis Pain, Wounds, Acute Ischemic Stroke, Adenocarcinoma Of The Gastroesophageal Junction, Amyotrophic Lateral Sclerosis, Atopic Dermatitis (Atopic Eczema), Burns, Cancer Pain, Crohn’s Disease (Regional Enteritis), Dupuytren Contracture, Epilepsy, Fibrosis, Gastric Cancer, Genital Herpes, Herpes Labialis (Oral Herpes), Herpes Zoster (Shingles), Herpetic Keratitis, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Liver Fibrosis, Lung Adenocarcinoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Myocardial Infarction, Ocular Pain (Eye Pain), Opium (Opioid) Addiction, Pancreatic Islet Transplant Rejection, Pulmonary Fibrosis, Squamous Non-Small Cell Lung Carcinoma and Unspecified.
The latest report Matrix Metalloproteinase 9 – Pipeline Review, H2 2020, outlays comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Companies Mentioned
- Aquilus Pharmaceuticals Inc
- EA Pharma Co Ltd
- Elastomics AB
- Gilead Sciences Inc
- Iproteos SL
- MabTrix Ltd
- Pharmahungary Group
- Proteris Biotech Inc
- Shulov Innovative Science Ltd
- Translational Sciences Inc
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Topics Covered:
1. Introduction
- Report Coverage
2. Overview
3. Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
4. Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
5. Companies Involved in Therapeutics Development
- Aquilus Pharmaceuticals Inc
- EA Pharma Co Ltd
- Elastomics AB
- Gilead Sciences Inc
- Iproteos SL
- MabTrix Ltd
- Pharmahungary Group
- Proteris Biotech Inc
- Shulov Innovative Science Ltd
- Translational Sciences Inc
6. Drug Profiles
7. Dormant Products
8. Discontinued Products
9. Product Development Milestones
- Featured News & Press Releases
- Nov 07, 2018: California research team publishes promising results from peptide based universal cancer vaccine
- Nov 02, 2016: Abzena Provides Update on GS-5745
- Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
- May 13, 2015: Abzena provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology
10. Appendix For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sah5p2
View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005940/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/09/2021 11:33 AM/DISC: 02/09/2021 11:33 AM
http://www.businesswire.com/news/home/20210209005940/en
